Introduction {#sec1}
============

Infections, autoimmune diseases or cancers can stimulate or inhibit an immune response, thus studies on these issues focus on understanding the molecular basis of T-cell reactivity, including their activation, which has been linked to two independent signals, i.e., TCR receptor present on the surface of T-cells (signal I) and co-stimulatory molecules, expressed abundantly on antigen-presenting cells (APC) (signal II) \[[@cit0001], [@cit0002]\]. These important elements regulating T-cell responses are some of the immunomodulatory molecules best described so far -- proteins of the B7 family \[[@cit0003]\], which stimulate the immune response of T lymphocytes, e.g. B7.1 (CD80), B7.2 (CD86) and ICOS (inducible T-cell co-stimulator) molecules \[[@cit0004]\] as well as suppressing molecules, such as PDL-1 (PD1 ligand), PDL-2 (PD2 ligand), B7-H3 (B7 homolog 3) or B7-H4 (B7 homolog 4) \[[@cit0005]-[@cit0008]\]. Butyrophilins are a recently discovered large family of proteins within the members of the immunoglobulin superfamily which are analogous in this respect to the B7 protein family \[[@cit0009]\].

Structure and classification of butyrophilins {#sec2}
=============================================

The first butyrophilins were described in the 1980s as proteins present in epithelial cells of the mammary gland, which are involved in lactation -- particularly in the secretion, formation and stabilization of fat balls in cow's milk \[[@cit0010]\]. Butyrophilins, similarly as the B7 family of regulatory proteins, are glycoproteins built of two extracellular immunoglobulin domains, stabilized with disulfide bonds: constant IgC, and variable IgV and a transmembrane region ([Fig. 1](#f0001){ref-type="fig"}).

![Structural organization of butyrophilins and B7 family](CEJI-42-31514-g001){#f0001}

In addition, most butyrophilins contain a conserved domain encoded by a single exon -- B30.2, also referred to as PRYSPRY \[[@cit0004]\]. Among butyrophilins (BTN), three subfamilies BTN1A, BTN2A and BTN3A have an identical structure, although the BTN3A2 protein has no B30.2 domain \[[@cit0003], [@cit0004], [@cit0009], [@cit0011]-[@cit0013]\]. Butyrophilin-like proteins also have a conventional structure composed of two immunoglobulin domains and the B30.2 domain \[[@cit0003], [@cit0004], [@cit0009], [@cit0011]-[@cit0013]\]. In turn, SKINT proteins have three transmembrane regions, however, they do not contain the B30.2 domain \[[@cit0004]\], and some of them are additionally lacking one of the immunoglobulin domains -- IgV or IgC \[[@cit0012]\].

In humans, the family of butyrophilins includes 7 butyrophilin proteins (BTN1A1, BTN2A1, BTN2A2, BTN2A3, BTN3A1, BTN3A2, BTN3A3), 5 butyrophilin-like proteins (BTNL) (BTNL2, BTNL3, BTNL8, BTNL9, BTNL10) and the SKINT-like factor (SKINTL -- selection and upkeep of intraepithelial T-cells) \[[@cit0009], [@cit0011], [@cit0014]\], while in mice, 11 proteins of this family have been described: BTN1A1, BTN2A2, BTNL1, BTNL2, BTLN4, BTNL5, BTNL6, BTNL7, BTNL9, BTNL10 and SKINTL, which differ in humans and mice \[[@cit0013]\]. It was shown that seven human butyrophilin genes are arranged in three phylogenetic groups, i.e., BTN1, BTN2 and BTN3, which are located on the short arm of chromosome 6 (6p22.1) in the region of MHC class I molecules, and they determine three butyrophilin subfamilies mentioned above (BTN1, BTN2 and BTN3) \[[@cit0011], [@cit0014]\]. It was demonstrated that the BTN1 subfamily is encoded by a single gene: BTN1A1, while BTN2 (BTN2A1, BTN2A2, BTN2A3) and BTN3 (BTN3A1, BTN3A2, BTN3A3) subfamilies have three genes each \[[@cit0004], [@cit0011]\]. The proteins of these three subfamilies, i.e., BTN1, BTN2 and BTN3 show a high homology of amino acid residues reaching up to 50%, even though this homology between BTN2 and BTN3 subfamily is sometimes more than 80% \[[@cit0014], [@cit0015]\]. Similarly as genes coding for butyrophilins, the genes of butyrophilin-like proteins are grouped in three clusters, namely: BTNL3, BTNL8 and BTNL9, which in humans are located on the long arm of chromosome 5 (5q35) \[[@cit0004]\]. SKINT proteins belonging to the family of butyrophilins \[[@cit0016]\] are determined in humans by three groups of genes, i.e., Skint 1-6, Skint 7/8 and Skint 9-11 \[[@cit0012]\]. It has also been proven that mRNAs encoding BTN and BTNL proteins are present in T and B lymphocytes, neutrophils, eosinophils as well as on the bone marrow, brain, lung, liver, small intestine and colon cells \[[@cit0003], [@cit0011]\].

Butyrophilins, cells of the immune system and infections, and pathological states {#sec3}
=================================================================================

Butyrophilin importance in the body is associated with their stimulatory and inhibitory effects on cells of the immune system. An example can be the BTN2A1 butyrophilin, which is one of the few among these proteins that binds to DC-SIGN -- pectin type C receptor (DC-specific ICAM3-grabbing non-integrin, also referred to as CD209), which is present on monocytes and dendritic cells and acts as an internalization receptor of HIV-1, HCV, but also other pathogens \[[@cit0015]\]. It was described that BTN1A1, BTN2A2, BTNL2 proteins of the butyrophilin family exerted an inhibitory effect on the proliferation of CD4+ T-cells through the cell cycle arrest and suppressed the proliferating activity of CD8+ T-cells \[[@cit0017]-[@cit0019]\]. These proteins also reduce the expression of a variety of cytokines associated with T-cell activation, including IL-2 and IFN-γ \[[@cit0020]\]. Stefferl *et al*. \[[@cit0021]\] demonstrated that the administration of recombinant BTN1A1 reduced T-cell activation, thereby inhibiting the development of diseases, such as experimental autoimmune encephalomyelitis in rat models. These investigators \[[@cit0021]\] suggested that due to the similarity of this butyrophilin to myelin oligodendrocyte glycoprotein, it might also mediate the modulation of T lymphocyte activation. In turn, Swanson *et al*. \[[@cit0022]\] and Amman *et al*. \[[@cit0020]\], studying BTNL2 *in vitro*, demonstrated that this protein activated the expression of Foxp3 factor (forkhead box P3) -- a key transcription factor involved in the regulation of immune response, which is responsible for the formation of regulatory T-cells. This protein also delays the signal from B7 proteins, as a result of decreased proliferation of T-cells, leading to the inhibition of proteins, such as IL-2, IL-13, IL-17 or IFN-γ \[[@cit0022]\]. The BTNL2 butyrophilin also inhibits the Akt activity (serine-threonine protein kinases), and maintains the activity of FOXO1 factor (forkhead box protein O1), thereby increasing the expression of Foxp3 factor \[[@cit0022]\]. In the case of the BTN3A1 protein, it was demonstrated in humans that it inhibited T-cell proliferation and cytokine production by Th1 lymphocytes by blocking the level of the cFLIP controller (cellular FLICE (FADD-like IL-1β-converting enzyme) inhibitory protein), which led to the silencing of caspase-8, which is required for the activation of NF-κB transcription factor \[[@cit0023]\]. The BTN3A1 butyrophilin, known as CD277 receptor, is stabilized in the myeloid dendritic cells and macrophages by vascular endothelial growth factor (VEGF), and by the CCl3 (chemokine ligand 3) chemokine in ovarian cancer cells \[[@cit0023], [@cit0024]\]. The BTNL8 protein also plays an important role among butyrophilins, and it is expressed on neutrophils, T lymphocytes and myeloid lineage cells \[[@cit0025]\]. This butyrophilin, in the presence of the anti-CD3 protein, binds T-cells, and administered as BTNL8-Ig, increases mainly the proliferation of CD4+ and CD8+ T-cells, and enhances the synthesis of IFN-γ, TNF-α, IL-8 and IL-10 \[[@cit0025]\]. In turn, the BTN3A2 butyrophilin exhibits an immune co-stimulatory effect on immune processes in ovarian cancer in women, as the high mRNA level of that butyrophilin improves prognosis in epithelial ovarian cancer (EOC) \[[@cit0026]\]. It was also shown that the expression of this protein in ovarian cancer was positively correlated with intraepithelial infiltration of CD4+ and CD8+ T-cells \[[@cit0027]\], thus suggesting that it may be a good prognostic marker in EOC because it affects the modulation of immune cells, and hence it is involved in the immunity against this cancer \[[@cit0027]\].

Butyrophilins also affect Vγ9Vδ2 T lymphocytes -- the main population of T-cells with the γδ receptor in human blood, and these cells comprise 1-10% of all T-cells in healthy individuals, in particular in the intestinal mucosa and mucosal tissues and liver \[[@cit0028]-[@cit0030]\]. These lymphocytes are characterized by a high reactivity of small organic pyrophosphate molecules \[[@cit0028]\] and show a strong reaction towards tumor cells \[[@cit0023]\] and pathogens, such as *Plasmodium falciparum*, *Mycobacterium* (*M.*) *tuberculosis* and *M. leprae* \[[@cit0031]-[@cit0034]\]*.* It was shown that during the biosynthesis of isoprenoids, e.g. HMBPP ((E)-4-hydroxy-3-methyl-but-2-enyl, phosphate), which are produced via MEP (2-C-methyl-D-erytrtiol-4- phosphate) by Gram positive and Gram negative bacteria and pathogens and parasites, the detection of phosphoantigens occurred through BTN3A, which also activated Vγ9Vδ2 T-cells \[[@cit0004], [@cit0028], [@cit0035]-[@cit0037]\]. Although it was not fully explained how this process occurred, two models explaining the interactions were proposed. The first model assumes that BTN3A, as a molecule that presents an antigen, captures and presents phosphoantigen on the surface of Vγ9Vδ2 T-cells that recognize this complex directly by TCR \[[@cit0038]\]. The second model suggests that BTN3A1, as the only one of the three BTN3 isoforms is able to activate Vγ9Vδ2 lymphocytes \[[@cit0039]\]. On the other hand, other authors \[[@cit0040]\] indicated that all three isoforms of this butyrophilin are required to activate these cells, and hence Sandstrom *et al*. \[[@cit0033]\] suggested that it was conditioned by the B30.2 domain present in butyrophilins, which "senses" the increased concentration of phosphoantigens so that it can serve as a "sensor" to detect changes in the level of isoprenoid metabolites \[[@cit0033]\].

Butyrophilins, in addition to the effects on T-cells, also affect other cells of the immune system. It was proven that BTN3A expressed on the surface of monocytes and dendritic cells caused their increased survival by the inhibition of apoptosis; they also increased the expression of molecules of this protein on these cells, thereby activating the synthesis of IL-1, IL-8 and IL-12 \[[@cit0041]\]. It was shown that the activation of monocytes and DC cells by the addition of BTN3A could also increase the immune signaling through TLRs (Toll-like receptors), which might suggest that the subfamily of these butyrophilins enhance proinflammatory signals \[[@cit0038]\]. In addition, it was suggested that BTN3A butyrophilins expressed on NK cells, but also BTN3A2 butyrophilins, contributed to the increased synthesis of IFN-γ by these cells \[[@cit0042]\]. It was demonstrated that butyrophilins in the presence of IL-2 and IL-15 acted on local immune responses, including proliferation and IEL (intraepithelial lymphocyte) cell activity in the intestinal mucosa in mice \[[@cit0007]\]. In addition, it was reported that butyrophilin-like proteins regulated the expression of CD25 and caused increased secretion of IFN-γ by IEL cells \[[@cit0007]\].

In addition to the involvement of butyrophilin family proteins in the experimental autoimmune encephalomyelitis \[[@cit0020]\] as well as genetic metabolic diseases, diabetes, and cancer \[[@cit0014]\], their role in infections (tuberculosis, leprosy, *Plasmodium* sp.) was also demonstrated \[[@cit0032]-[@cit0034]\]. The participation of butyrophilins was also described in sarcoidosis \[[@cit0043], [@cit0044]\] as well as in other conditions \[[@cit0043], [@cit0045]-[@cit0048]\]. In sarcoidosis it was shown that the mutant BTNL2 protein could not localize in the cell membrane and lost its inhibitory function, which led to abnormal activation of T-cells, and thereby to the inflammation in this disease. Their role was also described in humans \[[@cit0043]\] in the course of myositis, as during this disease an increased rate of BTNL2 butyrophilin mutation was observed \[[@cit0043]\]. A correlation was also demonstrated in humans between the BTNL2 polymorphism and ulcerative colitis \[[@cit0048]\], rheumatoid arthritis \[[@cit0047]\], systemic lupus erythematosus \[[@cit0046]\] and chronic renal diseases \[[@cit0046]\], which showed that this protein was involved in these pathological conditions. Despite the discussed examples of the participation and role of the BTNL2 butyrophilin in pathological states \[[@cit0046]\], observations in this field are still required to better elucidate the interaction between butyrophilins, including the BTNL2 polymorphism and various pathological conditions in mammals.

Conclusions {#sec4}
===========

Butyrophilins, as a large family within the immunoglobulin superfamily, similarly as the B7 protein family, are present on many cells of the immune system and modulate their action. A picture of their effect both in terms of inhibiting and increasing the activity of these cells by these proteins, mainly T lymphocytes, indicates that there are new possible modulation pathways, and hence new interactions between the components of natural and acquired immunity in mammals both in physiological and pathological conditions.
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